Study Finds Cancer Patients with HIV Can Benefit from Immunotherapy

Researchers at Georgetown Lombardi Comprehensive Cancer Center recently examined whether immune checkpoint inhibitor (ICI) therapy is safe and effective in patients with advanced cancer who also live with HIV.
 
Among non-AIDS-defining illnesses, cancer is the leading cause of death in patients with HIV, with many of those affected at an increased risk during their lifetime. ICI therapy offers a new way to treat cancer, yet clinical trials have often excluded those with HIV due to concerns that it may have negative effects, such as virus reactivation.
 
The study, published in JAMA Oncology, focused on 73 patients with HIV found through medical literature whose cancer had been treated with ICI therapy. Many of the patients studied were found through reports and case series from oncologists who chose to treat their patients with cancer and HIV infection with the new cancer drugs.
 
The researchers found that patients with HIV did not experience increased adverse effects and HIV remained undetectable in 26 of the 28 (93%) with viral load before treatment.
 
“We hope our finding[s] will lead to increased study of checkpoint inhibitors in patients with HIV and cancer,” lead study investigator Chul Kim, MD, MPH, said in a press release. He explained that the checkpoint inhibitors may not only treat the cancer, but may also restore an “immune response against HIV in patients whose immune system is exhausted by its long fight with HIV.”
 
According to the American Cancer Society, immune checkpoint inhibitor therapy acts as an “off switch” for the proteins that cancer cells use to avoid being attacked by the body’s natural immune response. Antiretroviral drugs target and block different stages of the virus' life cycle, preventing it from replicating.
 
Kim and his co-author, Michael Cook, MD, also found that checkpoint inhibitors offered objective response rates in treating non-small cell lung cancer and melanoma that were similar to non-infected patients. The treatment also showed a benefit in those with Kaposi sarcoma, a cancer linked to HIV infection that has very little treatment options. The objective response in this patient population was 67%, according to the press release.
 
“And we found something that is really intriguing,” Kim added. “In 6 patients who had a detectable load of HIV in the blood before treatment, 5 had a decrease in their viral load after treatment. It could be that checkpoint inhibitors are helping to suppress HIV, though this finding needs to be verified in future studies.”
 
To further investigate these findings, Georgetown will soon launch a clinical trial to test ICI therapy as a first-line therapy in patients with lung cancer who have HIV or viral hepatitis.
 
References
  1. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. Cook MR, Kim C. JAMA Oncol. https://jamanetwork.com/journals/jamaoncology/article-abstract/2723583. Accessed January 8, 2019
  2. Study Finds HIV + Cancer Patients Benefit from Immunotherapy. Georgetown University Medical Center. https://gumc.georgetown.edu/news/Study-Finds-HIV-Positive-Cancer-Patients-Benefit-From-Immunotherapy. Accessed January 8, 2019
  3. Immune checkpoint inhibitors to treat cancer. American Cancer Society. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed January 8, 2019.



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$